197 related articles for article (PubMed ID: 36476076)
21. Hepatocellular carcinoma immune prognosis score predicts the clinical outcomes of hepatocellular carcinoma patients receiving immune checkpoint inhibitors.
Zhang R; Zhao H; Wang P; Guo Z; Liu C; Qu Z
BMC Cancer; 2023 Dec; 23(1):1181. PubMed ID: 38041022
[TBL] [Abstract][Full Text] [Related]
22. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
[TBL] [Abstract][Full Text] [Related]
23. Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma.
Lee JS; Chon YE; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Kang W; Choi MS; Gwak GY; Paik YH; Lee JH; Koh KC; Paik SW; Kim HY; Kim TH; Yoo K; Ha Y; Kim MN; Lee JH; Hwang SG; Kim SS; Cho HJ; Cheong JY; Cho SW; Park SH; Heo NY; Hong YM; Yoon KT; Cho M; Park JG; Kang MK; Park SY; Kweon YO; Tak WY; Jang SY; Sinn DH; Kim SU;
Yonsei Med J; 2021 Jan; 62(1):12-20. PubMed ID: 33381930
[TBL] [Abstract][Full Text] [Related]
24. Development and validation of prognostic risk prediction models for hepatocellular carcinoma patients treated with immune checkpoint inhibitors based on a systematic review and meta-analysis of 47 cohorts.
Ma D; Liu M; Zhai X; Li X; Jin B; Liu Y
Front Immunol; 2023; 14():1215745. PubMed ID: 37520554
[TBL] [Abstract][Full Text] [Related]
25. Combination of CRAFITY score with Alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.
Teng W; Lin CC; Su CW; Lin PT; Hsieh YC; Chen WT; Ho MM; Wang CT; Chai PM; Hsieh JC; Lin CY; Lin SM
Am J Cancer Res; 2022; 12(4):1899-1911. PubMed ID: 35530282
[TBL] [Abstract][Full Text] [Related]
26. Elevated serum alpha-fetoprotein levels are associated with poor prognosis of hepatocellular carcinoma after surgical resection: A systematic review and meta-analysis.
Chen HL; Chen YH; Du L; Song YP; Zhu B
Arab J Gastroenterol; 2021 Mar; 22(1):12-22. PubMed ID: 33551350
[TBL] [Abstract][Full Text] [Related]
27. Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients.
Sun X; Mei J; Lin W; Yang Z; Peng W; Chen J; Zhang Y; Xu L; Chen M
BMC Cancer; 2021 Jul; 21(1):775. PubMed ID: 34218801
[TBL] [Abstract][Full Text] [Related]
28. Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib.
Nakazawa T; Hidaka H; Takada J; Okuwaki Y; Tanaka Y; Watanabe M; Shibuya A; Minamino T; Kokubu S; Koizumi W
Eur J Gastroenterol Hepatol; 2013 Jun; 25(6):683-9. PubMed ID: 23395995
[TBL] [Abstract][Full Text] [Related]
29. Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors.
Xu S; Lai R; Zhao Q; Zhao P; Zhao R; Guo Z
Front Immunol; 2021; 12():794099. PubMed ID: 34950153
[TBL] [Abstract][Full Text] [Related]
30. The association between antibiotic use and outcomes of HCC patients treated with immune checkpoint inhibitors.
Zhang L; Chen C; Chai D; Li C; Guan Y; Liu L; Kuang T; Deng W; Wang W
Front Immunol; 2022; 13():956533. PubMed ID: 36059512
[TBL] [Abstract][Full Text] [Related]
31. Reclassification of therapeutic response of unresectable hepatocellular carcinoma to anti-angiogenic therapy and immunotherapy using alpha RECIST.
Xu Y; Yang Y; Ouyang J; Zhou Y; Li L; Ye F; Yang H; Huang Z; Zhou A; Zhang W; Zhou J; Zhao X; Zhao H
Eur Radiol; 2024 Apr; 34(4):2244-2255. PubMed ID: 37740779
[TBL] [Abstract][Full Text] [Related]
32. Prognostic role of pre-treatment serum AFP-L3% in hepatocellular carcinoma: systematic review and meta-analysis.
Cheng J; Wang W; Zhang Y; Liu X; Li M; Wu Z; Liu Z; Lv Y; Wang B
PLoS One; 2014; 9(1):e87011. PubMed ID: 24498011
[TBL] [Abstract][Full Text] [Related]
33. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival.
Riaz A; Ryu RK; Kulik LM; Mulcahy MF; Lewandowski RJ; Minocha J; Ibrahim SM; Sato KT; Baker T; Miller FH; Newman S; Omary R; Abecassis M; Benson AB; Salem R
J Clin Oncol; 2009 Dec; 27(34):5734-42. PubMed ID: 19805671
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of immune checkpoint inhibitors for hepatocellular carcinoma patients with macrovascular invasion or extrahepatic spread: a systematic review and meta-analysis of 54 studies with 6187 hepatocellular carcinoma patients.
Han CL; Tian BW; Yan LJ; Ding ZN; Liu H; Mao XC; Tian JC; Xue JS; Tan SY; Dong ZR; Yan YC; Hong JG; Chen ZQ; Wang DX; Li T
Cancer Immunol Immunother; 2023 Jul; 72(7):1957-1969. PubMed ID: 36811662
[TBL] [Abstract][Full Text] [Related]
35. Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial.
Kudo M; Okusaka T; Motomura K; Ohno I; Morimoto M; Seo S; Wada Y; Sato S; Yamashita T; Furukawa M; Aramaki T; Nadano S; Ohkawa K; Fujii H; Kudo T; Furuse J; Takai H; Homma G; Yoshikawa R; Zhu AX
J Gastroenterol; 2020 Jun; 55(6):627-639. PubMed ID: 32107609
[TBL] [Abstract][Full Text] [Related]
36. Development and Assessment of Nomogram Based on AFP Response for Patients with Unresectable Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors.
Zhang Y; Shen H; Zheng R; Sun Y; Xie X; Lu MD; Liu B; Huang G
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958306
[TBL] [Abstract][Full Text] [Related]
37. Early Tumor Marker Response Predicts Treatment Outcomes in Patients with Unresectable Hepatocellular Carcinoma Receiving Combined Lenvatinib, Immune Checkpoint Inhibitors, and Transcatheter Arterial Chemoembolization Therapy.
Luo MC; Wu JY; Wu JY; Lin ZT; Li YN; Zeng ZX; Wei SM; Yan ML
J Hepatocell Carcinoma; 2023; 10():1827-1837. PubMed ID: 37850079
[TBL] [Abstract][Full Text] [Related]
38. Patients with melanoma treated with immune checkpoint inhibitors who had non-thyroid endocrine and skin immune-related adverse events have better prognosis: A systematic review and meta-analysis.
Sun Q; Sun H; Wu N; Hu Y; Zhang F; Cong X
Front Oncol; 2022; 12():976224. PubMed ID: 36185176
[TBL] [Abstract][Full Text] [Related]
39. Predictive Value of the Hepatic Immune Predictive Index for Patients with Primary Liver Cancer Treated with Immune Checkpoint Inhibitors.
Hong C; Dong HZ; Li RN; Zhu HB; Li QM; Cui H; Hu CY; Huang CY; Peng J; Liu L; Zou XJ; Xiao LS
Dig Dis; 2023; 41(3):422-430. PubMed ID: 36257291
[TBL] [Abstract][Full Text] [Related]
40. Association between posttreatment α-fetoprotein reduction and outcomes in real-world US patients with advanced hepatocellular carcinoma.
Abou-Alfa GK; Wang X; Parrinello CM; Gossai A; Kim R; Magee K; Miksad RA
Cancer; 2023 Jul; 129(13):2064-2074. PubMed ID: 36942492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
